L'intérêt à découvert pour Conduit Pharmaceuticals donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Conduit Pharmaceuticals. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Conduit Pharmaceuticals (NASDAQ:CDT) Stock, Rapport sur les intérêts à découvert

Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

In the latest quarter, 4 analysts provided ratings for Stifel Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SF#NYSE">SF</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $100.25, a high estimate of $115.00, and a low estimate of $84.00. This current average represents a 10.29% decrease from the previous average price target of $111.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1751922038_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Stifel Financial is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$115.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$102.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Michael Cho</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$84.00</td>
<td>$124.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Stifel Financial. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Stifel Financial compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Stifel Financial's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Stifel Financial's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SF/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Stifel Financial analyst ratings.</a>
<h2>Unveiling the Story Behind Stifel Financial</h2>
Stifel Financial Corp is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 67% of the company's net revenue is derived from its world-wide wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.
<h3>Unraveling the Financial Story of Stifel Financial</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Stifel Financial's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 7.97%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Stifel Financial's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 3.53%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Stifel Financial's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.89%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Stifel Financial's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.11%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Stifel Financial's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.31.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What Analysts Are Saying About Stifel Financial Stock

It's that time of the year. The pomp and circumstance of Independence Day are behind us.
The smell of something else is in the air. It's the prediction factory kicking into high gear.
The second half of the year is upon us, and the soothsayers, wizards, prognosticators, and Instant Experts of the Internet are rushing forth with their predictions for the rest of 2025.
The incense of the predictive priesthood of modern finance is beginning to rise once again. The chicken innards are being spilled, the leaves are being swirled about the cup, and the alignment of the stars is studied. The magic cards are being dealt, the lines are drawn on the chart, and pompous pontifications are being prepared.
<h2 class="wp-block-heading">Global Events Move Markets—Pro Helps You Move First</h2>
From surprise tariff announcements to sudden ceasefire headlines, Benzinga Pro delivers real-time alerts that move markets. With global tensions escalating, timing is everything—and seconds matter. Today, you can get filtered news, smart alerts, and our exclusive stories before other sources, all for 60% off. <a href="https://www.benzinga.com/pro/register/4th-of-july-sale/?utm_campaign=bzpro-4th&amp;utm_adType=sponsorad&amp;utm_ad=RDwebpost070725" target="_blank" rel="noreferrer noopener">This 4th of July sale ends today, Monday, so act now before you miss out.</a>
As Charlie Munger once opined, &#8220;People have always had this craving to have someone tell them the future. Long ago, kings would hire people to read sheep guts. There&#8217;s always been a market for people who pretend to know the future. Listening to today&#8217;s forecasters is just as crazy as when the king hired the guy to look at the sheep guts.&#8221;
Instead of predicting the market, react to what it&#8217;s already doing. 
Right now, economists are beating the government reports with great clubs of formula and truncheons of theories in hopes that the battered carcass of data will yield some accurate suggestions of what comes next for the economy and the market.
The number of jobs added last month was fantastic. That is good. Government jobs accounted for more than half of the new jobs added. That is bad.
Infomercial note: Most so-called experts, particularly online &#8220;instant experts,&#8221; rarely thoroughly review the data. The additional government jobs were in state and local governments. Federal employment shrank last month. If the idea is to cut the size of the federal government and push responsibility to the states, that is exactly what we want to see.
New unemployment claims fell and continuing claims flatlined. That&#8217;s good.
This means the Fed is less likely to hike rates in July. In fact, barring a disaster, that will not happen. That is bad.
The U.S. is the clear leader in developing Artificial Intelligence, which should lead to massive productivity improvements. That is good.
AI will replace millions of jobs. That is bad.
President Trump&#8217;s so-called &#8220;Big Beautiful Bill,&#8221; signed into law on the Fourth of July, contains provisions that should lead to corporate profit increases in the second half of the year. That is good.
It raises the deficit by billions of dollars. Maybe even trillions. That is bad.
And so it goes.
Most forecasters will pick either the good lane and be very optimistic about the world and stock prices, while others will choose to stay in the bad lane.
Anyone whose forecast is even slightly accurate will spend tons of cash advertising their brilliance to the world and become somewhat famous.
If history is any guide, they will never be right again.
The big money in the markets is not in predicting what may happen.
It is in reacting to what happens.
The best traders of all time wait for the price to confirm the hypothesis before acting.
The great ones have strict risk control and embrace small losses as the key to success.
If the price does not support the expectation, they move to the sidelines until it does.
When the price proved their assumptions correct, they piled on and made billions.
Right now, stocks are in an uptrend.
Period. Stop. End of Message.
You can hate the Fed.
You can love the Fed.
You can hate the President.
You can love the President.
You can be terrified about the future of the country or think the future is so bright you need to pick up some better sunglasses.
You can be against lowering interest rates or think it is the greatest idea in the history of the world.
What you think about any of this is irrelevant. Stocks are in an uptrend across all time frames.
As Ed Seykota, one of the early devotees of trend-following and one of the best traders of all time, once put it: The best investors have learned to embrace the fact that the fundamentals of the business and the price you pay to own it are far more important than predictions.
Peter Lynch has the greatest track record of any mutual fund manager ever, as far as I can tell. He once suggested that &#8220;If you spend 13 minutes a year on economics, you&#8217;ve wasted 10 minutes.&#8221;
This is one area where I have to be cautious: I do not just enjoy debating and discussing politics, law, and economics. I love it.
I must set aside opinions and theories when it comes to investing money.
The numbers matter much more than the theories.
Buying stocks with strong fundamentals is a market-beating strategy.
Buying companies with strong fundamentals when they are out of favor and available at a bargain price, relative to their asset value and earnings power, is a market-crushing strategy.
Traders should follow trends and ignore the news.
Investors should focus on fundamentals and valuation and ignore the news.
If history is a guide, you will make more money.
Given the results that most investors and traders have achieved by following the so-called Wall Street experts and alleged trading savants, it would be hard to do worse by following these two approaches, which have made more millionaires than everything else combined.
Examining the world through various value-based valuation price lenses, we find that stocks are in a strong uptrend across all time frames, with no signs of momentum fading.
Bonds are still in a long-term uptrend but are building a long trendless base in shorter time frames.
Depending on which economist you have been reading, we should be in the mother of all rallies in bonds or enduring the most painful yield spike in history, but neither is the case just yet.
There are not a lot of cheap stocks with excellent fundamentals at the moment. The few that exist are currently clustered around real estate and energy.
Since I know that most of you read this mainly for stock ideas, I will give you one safe and cheap stock that has the potential to be a massive long-term winner.
The offshore oil and gas industry is priced as if crude oil demand will be replaced by renewable and nuclear energy sometime in the near future.
That is not even close to being true.
Helix Energy Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLX#NYSE">HLX</a>) is a specialty offshore energy services company that focuses on maximizing production from mature offshore oil and gas wells, performing well decommissioning, and supporting offshore wind and subsea infrastructure projects.
Its core segments include Well Intervention, Robotics, Shallow Water Abandonment, and Production Facilities. Helix operates a fleet of advanced vessels and remotely operated vehicles, and its business is increasingly global, with significant operations in Brazil, the North Sea, and the Gulf of Mexico. The company is also playing a growing role in the energy transition, with contracts in offshore wind trenching and seabed restoration that align with its stated mission of enabling sustainable offshore energy.
The key here is that Helix&#8217;s balance sheet is in excellent shape. The company ended the quarter with $370 million in cash and a net debt position of negative $59 million. Credit agencies rate its senior unsecured notes at BB– to B+, and upcoming maturities are minimal. Leverage remains modest at roughly 2.3 times EBITDA, and interest coverage is healthy. Helix scores 8 out of 9 on the Piotroski F-score, signaling strong financial health across profitability, leverage, and efficiency metrics.
The stock is relatively inexpensive, and thanks to its strong balance sheet and focus on generating cash flow, Helix Energy is a relatively safe investment. The company has what it takes to survive until it thrives again.
When that happens, a return of several times the current stock price is not an unreasonable expectation.
I have no idea how the economy will play out or the outcome of the trade debacle, but I do know that whatever happens, it will be reflected in either trend or value and create an opportunity for us to profit by reacting to what does happen, rather than predicting what we think might occur.
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

Trading Ideas

2 Foolproof Ways To Profit In 2025's Market

In the preceding three months, 4 analysts have released ratings for ACV Auctions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NYSE">ACVA</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $21.0, a high estimate of $25.00, and a low estimate of $18.00. This current average has decreased by 3.45% from the previous average price target of $21.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1751922028_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of ACV Auctions by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$18.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ACV Auctions. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of ACV Auctions compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of ACV Auctions's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of ACV Auctions's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ACVA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ACV Auctions analyst ratings.</a>
<h2>Get to Know ACV Auctions Better</h2>
ACV Auctions Inc is a mobile platform for wholesale car auctions. The company provides a digital marketplace for wholesale vehicle transactions and data services that offer transparent and accurate vehicle information for customers.
<h3>ACV Auctions's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: ACV Auctions displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 25.4%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: ACV Auctions's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -8.11%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): ACV Auctions's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -3.37%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): ACV Auctions's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.39%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.38, ACV Auctions adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACVA

Forecasting The Future: 4 Analyst Projections For ACV Auctions

In the current market session, Lam Research Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) share price is at $98.05, after a 0.77% decrease. Over the past month, the stock went up by 7.85%, but over the past year, it actually fell by 11.79%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1751922018_0.png" alt="Past Year Chart" />

<h3>A Look at Lam Research P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Lam Research has a lower P/E than the aggregate P/E of 72.66 of the Semiconductors &amp; Semiconductor Equipment industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1751922018_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

News

Intraday Update

Markets

LRCX

P/E Ratio Insights for Lam Research

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Darling Ingredients (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAR#NYSE">DAR</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $42.75, a high estimate of $46.00, and a low estimate of $40.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 6.04%. 
<img src="https://www.benzinga.com/files/images/story/2025/1751922016_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Darling Ingredients among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lloyd Byrne</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$46.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Thomas Palmer</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$44.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$41.00</td>
<td>$51.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Darling Ingredients. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Darling Ingredients compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Darling Ingredients's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DAR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Darling Ingredients analyst ratings.</a>
<h2>Unveiling the Story Behind Darling Ingredients</h2>
Darling Ingredients Inc develops and manufactures sustainable ingredients for customers in the pharmaceutical, food, pet food, fuel, and fertilizer industries. It collects and transforms all aspects of animal by-product streams into ingredients, including gelatin, fats, proteins, pet food ingredients, fertilizers. Also, the company recovers and converts used cooking oil and bakery remnants into feed and fuel ingredients. Darling has three primary business segments which are feed ingredients contributing the majority of revenue, food ingredients, and fuel ingredients. It provides grease trap services for food businesses and sells various equipment for collecting and delivering cooking oil. The company derives the majority of its revenue from customers in North America.
<h3>Darling Ingredients: A Financial Overview</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Negative Revenue Trend: Examining Darling Ingredients's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -2.8% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Darling Ingredients's net margin excels beyond industry benchmarks, reaching -1.89%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.59%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Darling Ingredients's ROA stands out, surpassing industry averages. With an impressive ROA of -0.26%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Darling Ingredients's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.93, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Darling Ingredients Stock

Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) has outperformed the market over the past 5 years by 23.13% on an annualized basis producing an average annual return of 37.47%. Currently, Cheniere Energy has a market capitalization of $52.91 billion. 
Buying $100 In LNG: If an investor had bought $100 of LNG stock 5 years ago, it would be worth $478.94 today based on a price of $238.56 for LNG at the time of writing.
<h3>Cheniere Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751922014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Needham analyst Mayank Tandon downgrades WNS (Holdings) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) from Buy to Hold.

Downgrades

Needham Downgrades WNS (Holdings) to Hold

While multinational pharmaceutical firm Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) represents one of the top drugmakers in the world, that status alone hasn't exempted its equity from underperformance. In the past 52 weeks, LLY stock finds itself down almost 16%. Since the beginning of this year, LLY has barely poked its head above parity. Nevertheless, the statistical winds may point to an eventual recovery which options traders could potentially exploit.
Fundamentally, in the post-pandemic era, sentiment toward Eli Lilly skyrocketed thanks to its <a href="https://www.benzinga.com/news/25/01/42933134/fda-approves-weight-loss-drug-zepbound-for-sleep-apnea-will-insurance-cover-this-1000-per-month-medication">weight-loss drug</a>. In 2023, the U.S. Food and Drug Administration (FDA) approved the Zepbound (tirzepatide), the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. An injectable prescription medication that helps adults with other weight-related problems, Zepbound's clinical trials showed promising results.
Thanks to this early success, Eli Lilly and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) effectively formed a duopoly in the weight-loss market. While this reality contributed to a significant valuation surge, competition started to heat up last year. With major pharmaceuticals like Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Roche Holding Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announcing advancements in the <a href="https://www.benzinga.com/general/biotech/24/07/39849867/exclusive-weight-loss-duopoly-breaks-as-eli-lilly-novo-plummet-market-wont-be-dominated-by-just-2">development of obesity-fighting drugs</a>, LLY stock entered into a frustrating consolidation channel.
Still, with the pharmaceutical giant incurring an extended period of red ink in the market, JPMorgan analyst Chris Schott is essentially making the case that Eli Lilly is undervalued. Specifically, prescriptions for Zepbound and Mounjaro (an injectable <a href="https://www.lilly.com/news/media/media-kits/mounjaro">medicine</a> for adults with type 2 diabetes) are running ahead of expectations in the second quarter. As such, this performance may allow the pharmaceutical to beat and raise guidance throughout 2025.
Even with the <a href="https://www.benzinga.com/content/45261458/is-eli-lilly-a-buy-after-weak-earnings-and-cvs-novo-partnership">formulary change</a> by CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) putting around 200,000 patients at risk of losing access, Schott states that Eli Lilly's market share — which stands at about 70% to 75% of new patients — and strong momentum may help the company easily absorb the impact.
<h2 class="wp-block-heading">Statistical Backdrop Could Point To A Recovery In LLY Stock</h2>
Although the fundamental narrative of LLY stock is intriguing, it may also be a presuppositional leap. Essentially, the conclusion that LLY is undervalued is already embedded in the premise (that the market is not fully pricing in the good news for Eli Lilly).
If one thinks about it, it's an extraordinary claim. LLY stock routinely ranks among the most actively traded securities. That the market is somehow mispricing the pharmaceutical giant is an assertion that requires extraordinary evidence. In my opinion, if such evidence exists, it will likely materialize in the statistical realm as it's the arena that few (if any) analysts venture into.
A significant barrier to statistical analysis of the financial markets is the deployment of continuous scalar signals, such as share price or various valuation ratios. Because these signals are non-stationary, it's difficult (if not outright impossible) to extract meaningful insights based on the frequency of past analogs. Especially for highly traded securities like LLY stock, the measurement metrics constantly fluctuate.
To remedy this problem, we can impose stationarity by converting scalar signals into discrete states. For analyzing securities, converting share price into market breadth or sequences of accumulative and distributive sessions carries significant advantages. First, market breadth is essentially a representation of demand and demand is effectively binary. Second, clusters of binary codes can form distinct behavioral states, which can then serve as past analogs for extracting forward probabilities.
As an example, in the trailing two months, the price action of LLY stock can be interpreted as a "6-4-D" sequence: six up weeks, four down weeks, with a negative trajectory across the 10-week period. Admittedly, this process pancakes LLY's magnitude dynamism into a simple binary code. But the benefit is that this code can be easily segregated into distinct market profiles. From there, we can observe the likelihood of transition from one state to another.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-975331" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
With the above framework, we can identify that since January 2019, the 6-4-D sequence has materialized 38 times. From past analogs, we can also determine that in 68.42% of cases, the following week's price action results in upside, with a median return of 2.47%.
Accounting for the volatility on Monday, a realistic target over the next three weeks — assuming that the bulls gain and maintain control of the market — is just under the $800 level.
<h2 class="wp-block-heading">Playing The Odds With Eli Lilly</h2>
Based on the market intelligence above, bold speculators may consider the 785/790 bull call spread expiring Aug. 1. This transaction involves buying the $785 call and simultaneously selling the $790 call, for a net debit paid of $255 (the most that can be lost in the trade). Should LLY stock rise through the short strike price ($790) at expiration, the maximum reward is $245, a payout of 96%.
To be sure, the 780/790 bull spread expiring on the same day offers a payout of nearly 113%. However, the net debit required is $470, which puts significantly more capital at risk for only a modest increase in payout. Therefore, the 785/790 call spread is arguably more tempting.
Either way, both transactions require LLY stock to hit or exceed $790 on Aug. 1, which empirically appears to be a reasonable target. As a baseline, the chance that a long position in LLY will be profitable on any given week is quite high at 60.29%. However, the market's response to the 6-4-D sequence amplifies the odds in favor of the bullish speculator, thus incentivizing a debit-based strategy.
The opinions and views expressed in this content are those of the individual author and do not necessarily reflect the views of Benzinga. Benzinga is not responsible for the accuracy or reliability of any information provided herein. This content is for informational purposes only and should not be misconstrued as investment advice or a recommendation to buy or sell any security. Readers are asked not to rely on the opinions or information herein, and encouraged to do their own due diligence before making investing decisions.
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/options/25/07/46253955/khc-stock-bearish-pressure-statistical-reversal">Options Corner: Why Kraft Heinz Could Flip The Script On The Bears</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Long Ideas

Options

RHHBY

Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround

Leerink Partners analyst Joseph Schwartz maintains KalVista Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) with a Outperform and raises the price target from $18 to $20.

Price Target

KALV

Leerink Partners Maintains Outperform on KalVista Pharma, Raises Price Target to $20

Elon Musk announced the <a href="https://www.benzinga.com/news/politics/25/07/46265725/elon-musk-announces-formation-of-america-party-emerges-in-wake-of-donald-trumps-historic-spending-bill">launch of the American Party</a>, a rival political faction that could potentially unseat congressional and Senate candidates currently up for re-election or disrupt the 2028 presidential election.
Now, people are questioning whether the Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO is preparing to run for office.
What Happened: Musk's formation of the American Party coincides with the billionaire being <a href="https://www.benzinga.com/news/politics/25/07/46210411/musk-third-party-odds-hit-47-can-the-tesla-chief-do-what-no-one-has-since-1853">at odds with </a>President Donald Trump and members of Congress over the so-called &#8220;Big Beautiful Bill.&#8221; The legislation, which Trump officially signed into law on July 4, is expected to <a href="https://www.benzinga.com/news/politics/25/07/46235830/trump-wants-rate-cuts-will-big-beautiful-bill-help-answer-big-fat-no">drastically increase America's debt</a>.
Polls conducted by Musk on the social media platform X have shown strong support for a third-party option.
The question "can Elon Musk run for president?" is seeing increased interest on <a href="https://trends.google.com/trends/explore?geo=US&amp;q=can%20elon%20musk%20be%20president&amp;hl=en">Google Trends</a>, ranking at a tie for its multi-year high with the week of the 2024 presidential election.
The answer is no, as Musk was born in South Africa — not the U.S. While Musk later became a U.S. citizen in 2002, that&#8217;s not enough to qualify as a viable presidential candidate. According to the U.S. Constitution, there are three main <a href="https://www.usa.gov/requirements-for-presidential-candidates">requirements</a>:
<ul class="wp-block-list">
<li>Be a natural-born citizen of the United States</li>
<li>Be at least 35 years of age</li>
<li>Been a resident of the United States for 14 years</li>
</ul>
Therefore, Musk can't declare candidacy for president of the United States or even be vice president. However, he could run for office in several other roles if he chooses.
The Constitution lays out <a href="https://constitution.congress.gov/browse/essay/artI-S2-C2-1/ALDE_00013371/">requirements </a>of age, citizenship and residency for running for the House of Representatives and Senate, but neither requires having been a natural-born citizen. Musk could currently run for either office based on becoming a citizen in 2002 and being over 30 years of age.
Musk could also run for governor of any state like Texas, where he resides, or California, where he previously called home. There have been several prominent governors who haven't been natural-born U.S. citizens, including actor Arnold Schwarzenegger (California), who was born in Austria.
Musk could also run for the Speaker of the House leadership role. His name was floated around last December, alongside Trump, as <a href="https://www.benzinga.com/politics/24/12/42599154/elon-musk-as-speaker-of-the-house-rand-paul-shows-support-says-people-would-lose-their-ever-lovin-minds">potential Speaker of the House candidates</a>. The Constitution does not specify that the Speaker must be a member of Congress, although all past leaders have been elected officials and members of the majority party.
Did You Know?
<ul class="wp-block-list">
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent070725">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Musk, despite being the world's richest person and one of the most influential people in the U.S., cannot run for president. Trump <a href="https://www.benzinga.com/news/24/12/42640044/trump-fires-back-at-critics-and-denies-ceding-presidency-to-elon-musk-and-im-safe-he-wasnt-born-in-this-country">reminded the media</a> of this last year when critics said he had ceded the presidency to the Tesla CEO.
"No, he's not going to be president, that I can tell you," Trump said. "And I'm safe. You know why? He can't be. He wasn't born in the country."
This is probably good news for Tesla shareholders. The company&#8217;s stock has been highly volatile ever since Musk became involved in politics. Musk running for president or becoming the country's leader would likely result in him stepping away from Tesla fully, and the company would need a new CEO.
Musk has not promised to back a third-party candidate running for president. Instead, he intends to support candidates in upcoming congressional races against those who voted in favor of Trump&#8217;s spending bill, which he called "<a href="https://www.benzinga.com/markets/25/07/46235672/trump-says-elon-musk-would-close-up-shop-and-head-back-home-to-south-africa-without-subsidies-no-mor">utterly insane and destructive</a>."
As Benzinga previously reported, a potential third-party push in a presidential election by Musk would face an uphill battle. After all, Democrats and Republicans have won every presidential election since 1852.
Times have changed since then. Musk&#8217;s ownership of X and his massive following could ignite a third-party movement — especially with the billions he could pour into an election. Whether he&#8217;s serious, or can reshape political history for the first time in more than 170 years, remains to be seen.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/46168784/2028-election-poll-shows-vance-buttigieg-in-lead-where-trump-newsom-harris-rank-and-betting-odds">2028 Election Poll Shows Vance, Buttigieg In Lead: Where Trump, Newsom, Harris Rank — And Betting Odds</a></li>
</ul>
Image: Shutterstock

Education

Politics

General

TSLA

Can Elon Musk Run For President — Or Even Be Speaker Of The House?

Keybanc analyst Jason Celino maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Overweight and raises the price target from $185 to $192.

Keybanc Maintains Overweight on PTC, Raises Price Target to $192

Management

FELE

Franklin Electric Appoints Jennifer Wolfenbarger As CFO

Keybanc analyst Jason Celino maintains Bentley Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSY#NASDAQ">BSY</a>) with a Overweight and raises the price target from $56 to $59.

Keybanc Maintains Overweight on Bentley Systems, Raises Price Target to $59

Keybanc analyst Michael Leshock initiates coverage on Voyager Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYG#NYSE">VOYG</a>) with a Overweight rating and announces Price Target of $50.

Initiation

VOYG

Keybanc Initiates Coverage On Voyager Technologies with Overweight Rating, Announces Price Target of $50

HC Wainwright &amp; Co. analyst Emily Bodnar maintains Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) with a Buy and lowers the price target from $40 to $20.

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

HC Wainwright & Co. Maintains Buy on Jasper Therapeutics, Lowers Price Target to $20

Offerings

GAME

GameSquare Reveals Proposed Public Offering of Common Stock; Size Not Disclosed

<a href="https://truthsocial.com/@realDonaldTrump/posts/114813877378281211" title="https://truthsocial.com/@realDonaldTrump/posts/114813877378281211">https://truthsocial.com/@realDonaldTrump/posts/114813877378281211</a>

Macro Economic Events

Economics

President Trump Says U.S. Will Impose 36% Tariff On Thailand

Carpenter Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRS#NYSE">CRS</a>) has outperformed the market over the past 20 years by 3.68% on an annualized basis producing an average annual return of 12.12%. Currently, Carpenter Tech has a market capitalization of $13.97 billion. 
Buying $1000 In CRS: If an investor had bought $1000 of CRS stock 20 years ago, it would be worth $9,784.94 today based on a price of $280.73 for CRS at the time of writing.
<h3>Carpenter Tech's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751921113_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Carpenter Tech 20 Years Ago Would Be Worth Today

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Northern Dynasty Minerals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NAK#AMEX">NAK</a>) with a Buy and raises the price target from $1.3 to $2.5.

HC Wainwright & Co. Maintains Buy on Northern Dynasty Minerals, Raises Price Target to $2.5

<a href="https://truthsocial.com/@realDonaldTrump/114813871213779514">https://truthsocial.com/@realDonaldTrump/114813871213779514</a>

Comments

Conduit Pharmaceuticals

Intérêt court

Conduit Pharmaceuticals (NASDAQ:CDT) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL